NCT01585324View on ClinicalTrials.gov

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Hepatitis C, Chronic
Interventions
DRUG

peginterferon alfa-2a [Pegasys]

180 mcg subcutaneously weekly

DRUG

ribavirin [Copegus]

1000 mg or 1200 mg orally daily

Trial Locations (1)

43401

Most

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01585324 - A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) | Biotech Hunter | Biotech Hunter